^
Association details:
| Biomarker: | NPM1-ALK fusion |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Excerpt:
Karpas299 and SU-DHL-1 cells were selected due to the presence of a t(2;5) chromosomal translocation and expression of the NPM-ALK fusion protein...P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration.
DOI:
10.1158/1535-7163.MCT-07-0365
